Immune checkpoint inhibitor tumor regression may indicate which patients with hepatocellular carcinoma experience improved ...

Hepatocellular carcinoma, a type of liver cancer, is the sixth most common cancer worldwide and the third leading cause of ...

For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study ...

A new risk score model for hepatocellular carcinoma using standard clinical data can better identify individuals at risk ...

University of Iowa researchers have been awarded federal funding to help develop an effective drug combination to treat a ...

Researchers at the University of Iowa are part of a project designed to enhance treatment options for a common form of liver ...

Lenvatinib plus pembrolizumab has improved survival rates for patients with intermediate-stage hepatocellular cancer, ...

The FDA approved a phase 3 trial to assess amezalpat with the current standard of care in unresectable or metastatic ...

Hepatocellular carcinoma (HCC) is a significant global health concern, particularly in regions like the Asia-Pacific, where chronic viral hepatitis and liver diseases contribute to its high incidence ...

The summit, known for its pivotal discussions on advancements in cancer treatment, commenced with a focus on Hepatocellular ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced ...

Hua Zhuang; Yu-lan Peng; Tian-wu Chen; Yong Jiang; Yan Luo; Qiong Zhang; Zhi-gang Yang ...